Snail-Inspired Robotics: New Hope for Drug Delivery & Cancer Treatment

Researchers at The University of Manchester are developing miniature, snail-inspired soft robots designed to deliver anti-cancer drugs directly to tumors in the bowel, offering a potential breakthrough in precision medicine for colorectal cancer. The project, funded by nearly £1 million from UK Research and Innovation (UKRI), aims to improve drug targeting and reduce harmful side effects associated with traditional chemotherapy.

Current drug delivery methods often struggle to pinpoint tumor sites accurately, leading to systemic exposure and damage to healthy tissues. These new robots are designed to navigate the gastrointestinal tract with exceptional accuracy, anchoring themselves within malignant tissues and releasing therapeutic payloads in a controlled manner. This localized approach is expected to increase drug bioavailability at tumor sites while minimizing off-target toxicity, ultimately improving patient outcomes.

Inspired by Snail Locomotion

The innovative design draws inspiration from the unique locomotion of snails, and slugs. These creatures move using slow, controlled waves and adhesive mucus, allowing them to traverse uneven and slippery surfaces with remarkable precision. The research team is mimicking this slime-based locomotion, powered by rhythmic muscular waves, to engineer mini robots capable of navigating the complexities of the digestive system.

“This research brings together biology, materials science and robotics in a way that could genuinely transform future cancer therapies. By studying these remarkable organisms and translating their movement strategies into soft‑robotic systems, we hope to deliver a step change in how medicine is administered deep inside the body.”

Dr. Mostafa Nabawy

The robots will be constructed from peptide-based bionanomaterials, which can be precisely tuned at the molecular level. These materials are designed to respond to external triggers, such as magnetic fields, enabling doctors to remotely guide and control the robots’ movement within the body. This level of control is crucial for ensuring accurate drug delivery to the targeted tumor site.

Addressing Challenges in Soft Robotics and Biomechanics

The project builds upon previous research exploring snail-inspired robots, acknowledging that work in this area has been limited due to a lack of understanding of snail locomotion biomechanics and the challenges of simulating and constructing such robots. A prime goal of this project is to address these shortcomings by studying snail locomotion in detail and developing accurate models for simulation. This will allow researchers to optimize the robots’ design and control strategies before physical construction.

According to the University of Manchester, the research will focus on the actuation, sensing, and control strategies employed by snails to enable regiospecific controlled release of drug cargo while withstanding the physical, chemical, and mechanical stresses within the physiological environment. This is a significant challenge, as the human body presents a harsh and complex environment for delicate robotic systems.

UKRI Funding and Future Implications

The nearly £1 million in funding from UKRI’s Cross Research Council Responsive Mode (CRCRM) scheme underscores the project’s potential to transform colorectal cancer treatment. The CRCRM scheme supports emerging research that transcends disciplines, highlighting the interdisciplinary nature of this project, which combines biology, materials science, and robotics.

The development of these snail-inspired soft robots represents a significant step towards more targeted and effective cancer therapies. By delivering drugs directly to tumor sites, researchers hope to minimize the debilitating side effects often associated with chemotherapy and improve the quality of life for patients battling colorectal cancer. While still in the early stages of development, this innovative approach holds promise for revolutionizing cancer treatment in the future.

The research team includes Mohamed Elsawy, Katie Finegan, Lee Margetts, and William Sellers, working under the leadership of Principal Investigator Mostafa Nabawy. The project is based within the Mechanical and Aerospace Engineering, Earth and Environmental Sciences, and Pharmacy departments at The University of Manchester.